1-11 of 11
Francisco Hernandez-Ilizaliturri, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome

Athena Kritharis, MD, Jennifer A. Kanakry, Laurie H. Sehn, MDMPH, Tatyana Feldman, MD, Aimee Kroll, MS, Randy D. Gascoyne, MD, Adam M. Petrich, MD, Jeremy S. Abramson, MD, Francisco Hernandez-Ilizaliturri, MD, Zeina Al-Mansour, MD, Camille Adeimy, MD, Jessica Hemminger, MD, Nancy L. Bartlett, MD, Anthony R. Mato, MD, Paolo Caimi, MD, Ranjana Advani, MD, Andreas K. Klein, MD, Izidore S Lossos, MD, Oliver W. Press, MD PhD, Sonali M. Smith, MD, Jesus C Fabregas, MD, Chadi Nabhan, MD FACP, Timothy S. Fenske, MD, Jonathan W. Friedberg, MD, Julie M. Vose, MD MBA, Kristie A. Blum, MD, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2014) 124 (21): 1703.
https://doi.org/10.1182/blood.V124.21.1703.1703
Published: 2014
Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2013) 122 (21): 647.
https://doi.org/10.1182/blood.V122.21.647.647
Published: 2013
Journal Articles

Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models.

John Miller, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Ping-Chiao Tsai, PhD, Pavel Klener, Jr., MD, PhD, Francisco Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2012) 120 (21): 2756.
https://doi.org/10.1182/blood.V120.21.2756.2756
Published: 2012
Journal Articles

Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.

Matthew J. Barth, MD, Gopichand Pendurti, MD, Ping-Chiao Tsai, PhD, Cory Mavis, BSc, MSc, Pavel Klener, Jr., Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2012) 120 (21): 2757.
https://doi.org/10.1182/blood.V120.21.2757.2757
Published: 2012
Journal Articles

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Sarah Frys, BSc, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Juan Gu, PhD, John Gibbs, MD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2012) 120 (21): 1649.
https://doi.org/10.1182/blood.V120.21.1649.1649
Published: 2012
Journal Articles

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Juan Gu, PhD, Francisco Hernandez-Ilizaliturri, MD, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD
Journal: Blood
Blood (2012) 120 (21): 1655.
https://doi.org/10.1182/blood.V120.21.1655.1655
Published: 2012
Journal Articles

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Chanan-Khan, MD, Manish Patel, MD, Kevin R. Kelly, MD, Kelli L. Running, Mary Murphy, Robin Guild, Christina Carrigan, PhD, Sharron Ladd, Beni B. Wolf, MD, PhD, James J. O'Leary, MD, Sikander Ailawadhi, MD
Journal: Blood
Blood (2012) 120 (21): 728.
https://doi.org/10.1182/blood.V120.21.728.728
Published: 2012
Journal Articles

Clinicopathologic Characteristics of HIV-Associated Peripheral T-Cell Lymphoma.

Jorge Castillo, MD, Brady Beltran, MD, Jaime Collins, MD, Jose L Diez-Martin, MD, Francisco Hernandez-Ilizaliturri, MD, Steven M. Horwitz, MD, Julie M. Vose, M.D.
Journal: Blood
Blood (2009) 114 (22): 3924.
https://doi.org/10.1182/blood.V114.22.3924.3924
Published: 2009
Journal Articles

Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.

Francisco Hernandez-Ilizaliturri, MD, Ping-Chiao Tsio, MS, Ryan Campagna, BS, Cory Marvis, MS, Wasif Riaz, MD, Elizabeth Gruber, MS, John Gibbs, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2009) 114 (22): 288.
https://doi.org/10.1182/blood.V114.22.288.288
Published: 2009
Journal Articles

Lenalidomide (Revlimid®) Enhances Monoclonal Antibody-Associated Anti-Tumor Activity Against Rituximab-Sensitive and Rituximab-Resistant B-Cell Lymphoma Cell Lines.

Nishitha Reddy, MD, Raymond Cruz, MD, Francisco Hernandez-Ilizaliturri, MD, Joy Knight, BS, Myron S. Czuczman, MD
Journal: Blood
Blood (2006) 108 (11): 2522.
https://doi.org/10.1182/blood.V108.11.2522.2522
Published: 2006
Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Myron S. Czuczman, MD, Marion Skipper, RN, Alice Mohr, NP, Zale P. Bernstein, MD, Philip McCarthy, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Alban Chanan-Khan, MD
Journal: Blood
Blood (2004) 104 (11): 1396.
https://doi.org/10.1182/blood.V104.11.1396.1396
Published: 2004